APA (7th ed.) Citation

Livingstone, E., Gogas, H., Kandolf-Sekulovic, L., Meier, F., Eigentler, T. K., Ziemer, M., . . . Schadendorf, D. (2023). Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial. European journal of cancer, 190, . https://doi.org/10.1016/j.ejca.2023.112941

Chicago Style (17th ed.) Citation

Livingstone, Elisabeth, et al. "Early Switch from Run-in Treatment with Vemurafenib Plus Cobimetinib to Atezolizumab After 3 Months Leads to Rapid Loss of Tumour Control in Patients with Advanced BRAFV600-positive Melanoma: The ImmunoCobiVem Phase 2 Randomised Trial." European Journal of Cancer 190 (2023). https://doi.org/10.1016/j.ejca.2023.112941.

MLA (9th ed.) Citation

Livingstone, Elisabeth, et al. "Early Switch from Run-in Treatment with Vemurafenib Plus Cobimetinib to Atezolizumab After 3 Months Leads to Rapid Loss of Tumour Control in Patients with Advanced BRAFV600-positive Melanoma: The ImmunoCobiVem Phase 2 Randomised Trial." European Journal of Cancer, vol. 190, 2023, https://doi.org/10.1016/j.ejca.2023.112941.